Drug Profile
Research programme: somatostatin receptor agonists - Juvantia Pharma
Alternative Names: Somatostatin receptor agonists research programme - Juvantia PharmaLatest Information Update: 18 Feb 2009
Price :
$50
*
At a glance
- Originator Juvantia Pharma
- Class
- Mechanism of Action Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Coronary artery restenosis; Eye disorders; Pain; Prostate cancer; Skin disorders; Vascular restenosis
Most Recent Events
- 25 Jun 2005 Preclinical trials in Benign prostatic hyperplasia in Finland (unspecified route)
- 25 Jun 2005 Preclinical trials in Pain in Finland (unspecified route)
- 30 May 2005 This programme is still in active development